Bradda Head  Lithium exceeds targets, secures US$3 million royalty and moves closer to production. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

UK PM Johnson gets his first dose of AstraZeneca vaccine

Fri, 19th Mar 2021 18:44

LONDON, March 19 (Reuters) - British Prime Minister Boris
Johnson received his first dose of the AstraZeneca
COVID-19 vaccine on Friday and urged the public to do the same,
saying "he did not feel a thing."

Johnson, 56, was admitted to an intensive care unit last
year and given oxygen via a tube in his nose after he contracted
the virus and fell seriously ill. He later said he was so sick
that plans were drawn up on how to announce his death.

"I literally did not feel a thing. It was very good, very
quick," Johnson said after receiving the jab at St Thomas'
Hospital in London.

"I cannot recommend it too highly, everybody when you do get
your notification to go for a jab, please go and get it, it is
the best thing for you, best thing for your family and for
everyone else."

(Reporting by Andrew MacAskill; Editing by Kate Holton)

Related Shares

More News
3 Jul 2024 09:57

Aptamer shares jump as inks agreement with AstraZeneca

(Alliance News) - Aptamer Group PLC on Wednesday said it reached an agreement with AstraZeneca PLC.

2 Jul 2024 09:47

LONDON BROKER RATINGS: Deutsche Bank cuts Quilter, ups Polar Capital

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and on Monday:

1 Jul 2024 09:13

TOP NEWS: AstraZeneca cancer and Covid drugs recommended for approval

(Alliance News) - AstraZeneca PLC on Monday said two cancer treatments had been recommended for approval in the European Union, while there was also p...

1 Jul 2024 07:41

LONDON BRIEFING: Stocks called higher ahead of Thursday's election

(Alliance News) - Stocks in London are called to open higher on Monday, at the start of a politically fuelled week.

1 Jul 2024 07:17

AstraZeneca endometrial cancer treatment recommended for EU approval

(Sharecast News) - AstraZeneca announced on Monday that 'Imfinzi', or durvalumab, and 'Lynparza', or olaparib, have received a recommendation for appr...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.